GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Design Therapeutics Inc (NAS:DSGN) » Definitions » 50-Day SMA

Design Therapeutics (Design Therapeutics) 50-Day SMA : $3.27 (As of Apr. 27, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Design Therapeutics 50-Day SMA?

Moving averages are one of the core indicators in technical analysis. A Simple Moving Average (SMA) is simply the arithmetic average of stock price over a period. It is calculated by adding a selected range of prices, usually closing prices, and then dividing that figure by the number of time periods in that range.

The 50-Day SMA calculates the average price over 50 days. And the 20-Day SMA and 200-Day SMA calculates the average price over 20 days and 200 days separately.

As of today (2024-04-27), Design Therapeutics's 50-Day SMA is $3.27. It's 20-Day SMA is $3.76 and 200-Day SMA is $3.15.


Competitive Comparison of Design Therapeutics's 50-Day SMA

For the Biotechnology subindustry, Design Therapeutics's 50-Day SMA, along with its competitors' market caps and 50-Day SMA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Design Therapeutics's 50-Day SMA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Design Therapeutics's 50-Day SMA distribution charts can be found below:

* The bar in red indicates where Design Therapeutics's 50-Day SMA falls into.



Design Therapeutics  (NAS:DSGN) 50-Day SMA Calculation

The formula for calculating SMA is:

SMA=( P1 + P2 + ... + Pn ) / n

where:
Pn is the price of the stock at period n.
n is the total number of periods.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Design Therapeutics  (NAS:DSGN) 50-Day SMA Explanation

Simple Moving Average (SMA) is the arithmetic average of stock price over a period. The 20-Day SMA calculates the average price over 20 days. And the 50-Day SMA and 200-Day SMA calculates the average price over 50 days and 200 days separately. SMAs are often used to determine the price trend direction. A 200-Day SMA is usually a proxy for the long-term trend, while shorter periods indicate short-term trend.

SMA are commonly compared with stock price or different period SMAs to indicate a trading signal. Generally speaking, if the price goes above the SMA, or a short-term SMA crosses above a long-term SMA, an uptrend is expected, investors may want to go long or cover short. Conversely, if the price goes below the SMA, or the short-term SMA crosses below a long-term SMA, a downtrend is expected, investors may want to go short or exit long.

Two popular trading patterns that use SMA include the death cross and a golden cross. A death cross occurs when the 50-day SMA crosses below the 200-day SMA. This is considered a bearish signal, that further losses are in store. The golden cross is a bullish signal which occurs when a short-term SMA crosses above a long-term SMA.


Design Therapeutics 50-Day SMA Related Terms

Thank you for viewing the detailed overview of Design Therapeutics's 50-Day SMA provided by GuruFocus.com. Please click on the following links to see related term pages.


Design Therapeutics (Design Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
6005 Hidden Valley Road, Suite 110, Carlsbad, CA, USA, 92011
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations.
Executives
Rodney W Lappe director C/O MIRATI THERAPEUTICS INC., 4660 LA JOLLA VILLAGE DRIVE, SUITE 500, SAN DIEGO CA 92121
Deepa Prasad director C/O VTV THERAPEUTICS INC., 3980 PREMIER DRIVE, SUITE 310, HIGH POINT NC 27265
Arsani William director C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
Joao Md Siffert director, officer: President and CEO 20 ENTERPRISE, SUITE 200, ALISO VIEJO CA 92656
Simeon George director, 10 percent owner 161 WASHINGTON STREET, SUITE 500, CONSHOHOCKEN PA 19428
Sr One Capital Fund I Aggregator Lp 10 percent owner C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
Stella Xu director, 10 percent owner C/O ARMO BIOSCIENCES, INC., 575 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Julie Burgess officer: Chief Accounting Officer C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
Dawn Giangiulio officer: Principal Accounting Officer C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
Heather Behanna director C/O ENTASIS THERAPEUTICS HOLDINGS INC., 35 GATEHOUSE DRIVE, WALTHAM MA 02451
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Pratik Shah director, officer: Executive Chairperson 3366 N. TORREY PINES COURT, SUITE 220, LA JOLLA CA 92037
Sean Jeffries officer: Chief Operating Officer C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
Justin Thacker officer: Vice President, Finance C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
Aseem Z. Ansari 10 percent owner C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011

Design Therapeutics (Design Therapeutics) Headlines

From GuruFocus